Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection

AIDS Research and Human Retroviruses

Volumn 16, Issue 18, 2000, Pages 1929-1938

  Naisbitt, D J ^a   Vilar, F J ^b   Stalford, A C ^a   Wilkins, E G L ^b   Pirmohamed, M ^a   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOBIMANE; COTRIMOXAZOLE; CYSTEINE; GLUTATHIONE REDUCTASE; NITROSOSULFAMETHOXAZOLE; SULFAMETHOXAZOLE; SULFONAMIDE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; REACTION ANALYSIS; REDUCTION; STEVENS JOHNSON SYNDROME;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; DISEASE PROGRESSION; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; OXIDATION-REDUCTION; SULFAMETHOXAZOLE; SULFHYDRYL COMPOUNDS;

EID: 0034634911     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200750054657     Document Type: Article

References (69)

1. Importance of the glutathione cycle in drug metabolism
2. Metabolism and function of glutathione
3. Glutathione: Toxicological implications
4. Differential distribution of free and bound glutathione and cyst(e)ine in human blood
5. Glutathione
6. Glutathione: An overview of biosynthesis and modulation
7. Low concentrations of acid soluble thiol (cysteine) in the blood plasma of H1V-infected patients
8. Systemic glutathione deficiency in symptom free HIV seropositive individuals
9. Glutathione depletion in HIV-infected patients: Role of cysteine deficiency and effect of oral N-acetylcysteine
10. Glutathione deficiency and human immunodeficiency virus infection
11. Decreased release of glutathione into the systemic circulation of patients with HIV infection
12. Effect of N-acetylcysteine (NAc) treatment on HIV- 1 infection: A double-blind placebo-controlled trial
13. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: Toxicological and pathological implications
14. Loss of glutathione, oxidative stress and decrease of intracellular pH as sequential steps in viral infection
15. Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection
16. Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-acetylcysteine
17. Intracellular thiols regulate activation of nuclear factor kappaB and transcription of human immunodeficiency virus
18. Programmed cell death of T cells in HIV-1 infection
19. Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis
20. + lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection
21. Glutathione and cysteine in HIV-infected haemophiliacs
22. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency
23. Glutathione homeostasis is disturbed in CD4 positive lymphocytes of HIV-seropositive individuals
24. Drug hypersensitivity reactions and human immunodeficiency virus disease
25. Drug reactions in HIV-infected patients
26. Adverse reactions to co-trimoxazole in HIV infection
27. Pathogenesis and management of HIV-associated drug hypersensitivity
28. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?
29. HIV related skin diseases
30. The relationship between the disposition and immunogenicity of sulphamethoxazole in the rat
31. Differences in the metabolism of sulfonamides predisposing to idiosyncratic toxicity
32. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulphonamides
33. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV
34. Glutathione transferase μ deficiency is not a marker for predisposition to sulphonamide toxicity
35. Cellular toxicity of sulphamethoxazole reactive metabolites. I. Inhibition of intracellular esterase activity prior to cell death
36. Immunological analysis of sulphonamide drug allergy: Identification of sulphamethoxazole substituted human serum proteins
37. Immune response to sulphamethoxazole in patients with AIDS
38. + T cells in individuals allergic to sulphonamides, phenytoin, and carbamazepine
39. Covalent binding of sulphamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
40. Conjugation of sulphamethoxazole to protein and human white blood cells: Possible role in toxicity and protection by reductases
41. Sulphamethoxazole is metabolised to the hydroxylamine in humans
42. Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune-mediated toxicity
43. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions
44. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
45. Methodologies for the application of mono-bromobimane to the simultaneous analysis of soluble and protein thiol components in biological systems
46. Disposition of amodiaquine and related antimalarials in human neutrophils: Implications for drug design
47. Glutathione and HIV infection: Reduced reduced, or increased oxidized?
48. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma
49. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection
50. On the cycles of glutathione metabolism and transport
51. Gamma-glutamyl transpeptidase: Catalytic, structural and functional aspects
52. Metabolism and transport of glutathione and other γglutamyl compounds
53. Enzymatic assay for glutathione
54. The glutathione status of cells
55. Assay of glutathione, glutathione disulphide and glutathione mixed disulphides in biological systems
56. Immunopathogenic mechanisms of HIV-infection: Cytokine induction of HIV expression
57. HIV-1 Tat potentiates TNF-induced NF-ΚB activation and cytotoxicity by altering the cellular redox state
58. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 tat-transgenic mice
59. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria
60. Elevated plasma levels of reduced homocysteine in common variable immunodeficiency virus infection
61. Plasma homocysteine levels and mortality in patients with coronary artery disease
62. Severe premature coronary artery disease with protease inhibitors
63. Polyaromatic hydrocarbon (PAH) ortho-quinone conjugate chemistry: Kinetics of thiol addition of PAH ortho-quinones and structures of thioether adducts of naphthalene-1,2-dione
64. Effect of glutathione depletion and oral N-acetylcysteine treatment on CD4+ and CD8+ cells
65. Sulfonamide-induced reactions in desensitised patients with AIDS - The role of covalent protein haptenation by sulfamethoxazole
66. Glutathione deficiency is associated with impaired survival in HIV disease
67. N-Acetyl cysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients
68. A randomised trial of N-acetylcysteine for prevention of trimethoprimsulfamethoxazole hypersensitivity reactions in Canadian HIV Trials Network 057 Study Group
69. Uptake and distribution of N-acetylcysteine in mice - Tissue-specific effects on glutathione concentrations